Board of Directors
Andy Astor – President/CEO
An entrepreneurial technology executive with over 35 years of operating and financial experience, Andy Astor joined Nephros in early 2017, as Chief Financial Officer. He was named Chief Operating Officer in 2019, and Chief Executive Officer and Director in August 2020. Prior to Nephros, he was President and CFO of OpenSCG, a software technology firm that was acquired in 2018 by Amazon Web Services. From 2013 to 2015, Mr. Astor was Managing Director at Synechron, a global technology consultancy. From 2009 to 2013, he was Vice President, Technology at Asurion, where he led a 1,000-staff software development division. From 2004 to 2008, he was co-founder and CEO of EnterpriseDB, an open-source software firm for which he raised over $25 million in venture capital and spearheaded strategic partnerships with IBM and NTT Data. From 2002 to 2004 Mr. Astor was Vice President of Web Services Strategy at webMethods, a publicly traded company that was subsequently acquired by Software AG for $546 million. While at webMethods Mr. Astor also served on the Board of Directors of the Web Services Interoperability Organization (WS-I). Prior to that, he spent several years as Vice President of Transactional Products at Dun & Bradstreet (NYSE: DNB), and held various roles at Ernst & Young, MCI Systemhouse, and American Management Systems. Mr. Astor received his Bachelor of Arts in Mathematics from Clark University and his MBA from The Wharton School at the University of Pennsylvania.
Mr. Amron is a partner of Wexford Capital and serves as its General Counsel. He actively participates in various private equity transactions, particularly in the bankruptcy and restructuring areas, and has served on the board committees of a number of public and private companies in which Wexford has held investments. Mr. Amron holds a JD from Harvard University, a B.A. in political theory from Colgate University, and is a member of the New York bar.
Paul A. Mieyal
Dr. Mieyal is a Vice President and the Director of Life Sciences Investments of Wexford Capital LLC. Prior to that, he was Vice President in charge of health care investments for Wechsler & Co., Inc. a private investment firm and registered broker dealer. Dr. Mieyal serves as director of Nile Therapeutics, Inc., and several privatecompanies. Dr. Mieyal received his Ph.D. in pharmacology from New York Medical College, a B.A. in chemistry and psychology from Case Western Reserve University, and is a Chartered Financial Analyst.
Mr. Persen is currently the President of Resolute Performance Contracting, a solar construction firm that he founded in 2011. Previously, from 2009 through 2011, he was the Executive Vice President at Ironco Enterprises, a renewable energy contracting organization. From 2004 through 2008, Mr. Persen served as the Chief Financial Officer for Radyne Corporation, a NASDAQ-traded manufacturer and distributor of satellite and telecommunications equipment. While at Radyne, he was part of the management team that tripled revenues and sold the firm, resulting in a 100% return for shareholders. Earlier, Mr. Persen was employed as Group Financial Officer for Avnet, Inc., a global distributor of electronic components and computer systems. Other experience included assignments with consultancies Arthur D. Little and Mercer Management Consulting. In addition, Mr. Persen lectured in finance at the University of Arizona from 2010 to 2013 and at Boston College from 1988 to 1999. Mr. Persen currently serves on the Board of Valutek, a supplier of cleanroom supplies through direct and distribution channels. Mr. Persen holds a BA in Political Economics from The Colorado College, and an MBA from The Amos Tuck School of Business at Dartmouth College.
Mr. Oliver Spandow is currently the CFO, Executive Vice President and a member of the board of directors of IDOC, LLC, an optometry-based consulting and member service organization. Prior to IDOC, Mr. Spandow spent 15 years with Johnson and Johnson (J&J), including roles as the General Manager of the JNJ Vision Care business in the United Kingdom and Ireland, Vice President of Strategic Accounts and Business Insights at Vistakon (J&J) USA, and Vice President, Finance and CFO of Vistakon (J&J) USA. While at JNJ, in addition to general finance, sales and marketing roles, he was involved with multiple acquisitions, divestment, and licensing deals. Prior to J&J, Mr. Spandow was a Management Consultant with Price Waterhouse. Mr. Spandow holds a B.S. in Finance from the University of Connecticut and an MBA from the Fuqua School of Business, Duke University.
Ms. Alisa Lask is currently Vice President & General Manager at Galderma, a Nestle Skin Health company. She oversees the franchise of pharmaceutical, medical device injectable brands, and cosmeceutical skincare products. Previously, Ms. Lask was Senior Director of Global Strategic Marketing at Allergan, Vice President, Global Strategic Marketing at Zimmer Biomet, and spent 10 years at Eli Lilly in a number of positions of increasing responsibility, with her final role as Director, Global Neuroscience. Ms. Lask received her M.B.A. from the University of Michigan in Marketing and her B.A. in Marketing and Finance from Miami University of Ohio.
Mr. Tom Gwydir is currently Chief Information Officer (CIO) at the London Stock Exchange. Prior positions have included CIO and Chief Technology Officer at MSCI, Managing Director of Platform Services at UBS, and Vice President of Technology at Asurion. He has also held senior roles at Wells Fargo, Merrill Lynch, Dun & Bradstreet, and Magna Software. He received his B.S. in Industrial Engineering from Columbia University.